BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST
Bergen, Norway, 4 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the third quarter 2021 on Tuesday 16 November 2021. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo where BerGenBio’s senior management team will provide an update on the Company followed by a Q&A session. To attend in person please register by mail to hanna.haug@carnegie.no The presentation will webcast